RecruitingPHASE2, PHASE3NCT06328608
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
Studying Fabry disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Intervention
- PRX-102 1 mg/kg every two weeks(drug)
- Enrollment
- 22 enrolled
- Eligibility
- 2-17 years · All sexes
- Timeline
- 2025 – 2031
Study locations (12)
- Phoenix Children's, Phoenix, Arizona, United States
- Emory Genetics Clinical Trials Center, Atlanta, Georgia, United States
- University of Iowa, Iowa City, Iowa, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- University of Utah, Salt Lake City, Utah, United States
- Lysosomal and Rare Disorders Research and Treatment Center Inc, Fairfax, Virginia, United States
- UK für Kinder- und Jugendheilkunde der PMU Salzburg, Salzburg, Austria
- Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin, Bordeaux, France
- Hopital Arnaud de Villeneuve, Montpellier, France
- Haukeland Universitetssjukehus, Bergen, Norway
- Hospital Clinico Universitario De Santiago De Compostela, Santiago de Compostela, Spain
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
Collaborators
ICON plc
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06328608 on ClinicalTrials.govOther trials for Fabry disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06906367A Study of Patients With Fabry Disease (US Specific)Amicus Therapeutics
- RECRUITINGPHASE3NCT06904261A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA VariantsAmicus Therapeutics
- RECRUITINGNCT07235709Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR StudyYonsei University
- RECRUITINGNANCT07187440A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry DiseaseTakeda
- ENROLLING BY INVITATIONNANCT07495410Anderson-Fabry Disease Fitness Improvement Training: A-FAD-FITGeneral University Hospital, Prague
- RECRUITINGNANCT07382128Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy PhenotypesIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNCT06941025Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and BreastfeedingChiesi Farmaceutici S.p.A.
- RECRUITINGPHASE1NCT06858397A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry DiseaseGC Biopharma Corp